Hanlon Investment Management’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.15M Sell
32,442
-941
-3% -$27.8K 0.61% 43
2026
Q1
$925K Sell
33,383
-874
-3% -$22.5K 0.51% 60
2025
Q4
$743K Buy
+34,257
New +$676K 0.41% 89

Other funds holding ROIV

Hanlon Investment Management's ROIV Position: Q2 2026 in Review

Hanlon Investment Management reduced its Roivant Sciences (ROIV) stake by 2.8% in Q2 2026, selling an estimated $27.8K and leaving 32,442 shares worth $1.15M. The position accounts for 0.61% of the portfolio, ranked #43.

Hanlon Investment Management first reported a position in ROIV in Q4 2025 and has held it in 3 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Hanlon Investment Management held 32,442 shares of Roivant Sciences worth $1.15M as of Q2 2026.
  • Hanlon Investment Management sold 941 Roivant Sciences shares in Q2 2026, an estimated $27.8K.
  • Roivant Sciences made up 0.61% of Hanlon Investment Management's portfolio in Q2 2026, its #43 holding.
  • Hanlon Investment Management first reported a position in Roivant Sciences in Q4 2025 and has held it in 3 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Hanlon Investment Management's 13F filing for Q2 2026, filed 31 Jul 2026.